Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.
Wedbush raised the firm’s price target on Tourmaline Bio (TRML) to $43 from $42 and keeps an Outperform rating on the shares. All key ...
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback